Search results
Showing 1 to 5 of 5 results for selumetinib
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Awaiting development [GID-TA11457] Expected publication date: TBC
Selumetinib for treating differentiated thyroid cancer [ID1079]
Discontinued [GID-TA10207]
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.